{"title":"益生菌干预子宫内膜癌术后肠道菌群重建及改善患者生活质量的研究进展。","authors":"Wei Chen, Xiao Chen, Yi Fang, Yang Sun, Yibin Lin","doi":"10.3389/fcimb.2025.1670836","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to comprehensively assess the impact of probiotic supplementation on gut microbiota composition and quality of life in endometrial cancer (EC) patients, offering clinical insights supported by empirical data.</p><p><strong>Methods: </strong>A systematic search was conducted across multiple databases, including PubMed, EMBASE, Cochrane Library, Web of Science, and CNKI, covering literature up to mid-2023. Only randomized controlled trials (RCTs) investigating probiotic administration in EC surgery patients were selected. Key evaluation metrics encompassed gut microbial diversity indices, shifts in specific bacterial populations, quality of life assessments, gastrointestinal symptom severity, and immune response indicators. Statistical analyses were performed using RevMan 5.4 and Stata 16.0 software.</p><p><strong>Results: </strong>The meta-analysis incorporated 18 RCTs with a total of 1,246 participants. Findings revealed that probiotic supplementation significantly enhanced α-diversity (SMD = 0.68, 95% CI: 0.41-0.95, p < 0.001) and increased the prevalence of beneficial microbes, including Bifidobacterium (SMD = 1.12, 95% CI: 0.78-1.46, p < 0.001) and Lactobacillus (SMD = 0.93, 95% CI: 0.65-1.21, p < 0.001). Conversely, opportunistic pathogens like Bacteroidetes exhibited reduced abundance (SMD = -0.54, 95% CI: -0.82 to -0.26, p < 0.001). Clinically, probiotic use led to notable improvements in overall quality of life (MD = 8.74, 95% CI: 5.12-12.36, p < 0.001) and alleviated gastrointestinal disturbances, such as diarrhea (RR = 0.45, 95% CI: 0.32-0.63, p < 0.001) and constipation (RR = 0.57, 95% CI: 0.42-0.78, p < 0.001). Additionally, inflammatory markers, including IL-6 (SMD = -0.76, 95% CI: -1.05 to -0.47, p < 0.001) and TNF-α (SMD = -0.64, 95% CI: -0.93 to -0.35, p < 0.001), were significantly lowered. Subgroup analyses indicated superior efficacy with multi-strain formulations, higher dosages (≥10<sup>10</sup> CFU/day), and extended treatment durations (≥8 weeks).</p><p><strong>Conclusion: </strong>Current evidence supports the beneficial role of probiotics in restoring gut microbiota balance, enhancing patient well-being, mitigating digestive complications, and reducing systemic inflammation following EC surgery. Further high-quality research is warranted to refine optimal probiotic strains, dosing strategies, and intervention timing.</p>","PeriodicalId":12458,"journal":{"name":"Frontiers in Cellular and Infection Microbiology","volume":"15 ","pages":"1670836"},"PeriodicalIF":4.8000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491236/pdf/","citationCount":"0","resultStr":"{\"title\":\"Research progress of probiotics intervention on reconstruction of intestinal flora and improvement of quality of life in patients after endometrial cancer surgery.\",\"authors\":\"Wei Chen, Xiao Chen, Yi Fang, Yang Sun, Yibin Lin\",\"doi\":\"10.3389/fcimb.2025.1670836\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aims to comprehensively assess the impact of probiotic supplementation on gut microbiota composition and quality of life in endometrial cancer (EC) patients, offering clinical insights supported by empirical data.</p><p><strong>Methods: </strong>A systematic search was conducted across multiple databases, including PubMed, EMBASE, Cochrane Library, Web of Science, and CNKI, covering literature up to mid-2023. Only randomized controlled trials (RCTs) investigating probiotic administration in EC surgery patients were selected. Key evaluation metrics encompassed gut microbial diversity indices, shifts in specific bacterial populations, quality of life assessments, gastrointestinal symptom severity, and immune response indicators. Statistical analyses were performed using RevMan 5.4 and Stata 16.0 software.</p><p><strong>Results: </strong>The meta-analysis incorporated 18 RCTs with a total of 1,246 participants. Findings revealed that probiotic supplementation significantly enhanced α-diversity (SMD = 0.68, 95% CI: 0.41-0.95, p < 0.001) and increased the prevalence of beneficial microbes, including Bifidobacterium (SMD = 1.12, 95% CI: 0.78-1.46, p < 0.001) and Lactobacillus (SMD = 0.93, 95% CI: 0.65-1.21, p < 0.001). Conversely, opportunistic pathogens like Bacteroidetes exhibited reduced abundance (SMD = -0.54, 95% CI: -0.82 to -0.26, p < 0.001). Clinically, probiotic use led to notable improvements in overall quality of life (MD = 8.74, 95% CI: 5.12-12.36, p < 0.001) and alleviated gastrointestinal disturbances, such as diarrhea (RR = 0.45, 95% CI: 0.32-0.63, p < 0.001) and constipation (RR = 0.57, 95% CI: 0.42-0.78, p < 0.001). Additionally, inflammatory markers, including IL-6 (SMD = -0.76, 95% CI: -1.05 to -0.47, p < 0.001) and TNF-α (SMD = -0.64, 95% CI: -0.93 to -0.35, p < 0.001), were significantly lowered. Subgroup analyses indicated superior efficacy with multi-strain formulations, higher dosages (≥10<sup>10</sup> CFU/day), and extended treatment durations (≥8 weeks).</p><p><strong>Conclusion: </strong>Current evidence supports the beneficial role of probiotics in restoring gut microbiota balance, enhancing patient well-being, mitigating digestive complications, and reducing systemic inflammation following EC surgery. Further high-quality research is warranted to refine optimal probiotic strains, dosing strategies, and intervention timing.</p>\",\"PeriodicalId\":12458,\"journal\":{\"name\":\"Frontiers in Cellular and Infection Microbiology\",\"volume\":\"15 \",\"pages\":\"1670836\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491236/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Cellular and Infection Microbiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fcimb.2025.1670836\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cellular and Infection Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcimb.2025.1670836","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Research progress of probiotics intervention on reconstruction of intestinal flora and improvement of quality of life in patients after endometrial cancer surgery.
Objective: This study aims to comprehensively assess the impact of probiotic supplementation on gut microbiota composition and quality of life in endometrial cancer (EC) patients, offering clinical insights supported by empirical data.
Methods: A systematic search was conducted across multiple databases, including PubMed, EMBASE, Cochrane Library, Web of Science, and CNKI, covering literature up to mid-2023. Only randomized controlled trials (RCTs) investigating probiotic administration in EC surgery patients were selected. Key evaluation metrics encompassed gut microbial diversity indices, shifts in specific bacterial populations, quality of life assessments, gastrointestinal symptom severity, and immune response indicators. Statistical analyses were performed using RevMan 5.4 and Stata 16.0 software.
Results: The meta-analysis incorporated 18 RCTs with a total of 1,246 participants. Findings revealed that probiotic supplementation significantly enhanced α-diversity (SMD = 0.68, 95% CI: 0.41-0.95, p < 0.001) and increased the prevalence of beneficial microbes, including Bifidobacterium (SMD = 1.12, 95% CI: 0.78-1.46, p < 0.001) and Lactobacillus (SMD = 0.93, 95% CI: 0.65-1.21, p < 0.001). Conversely, opportunistic pathogens like Bacteroidetes exhibited reduced abundance (SMD = -0.54, 95% CI: -0.82 to -0.26, p < 0.001). Clinically, probiotic use led to notable improvements in overall quality of life (MD = 8.74, 95% CI: 5.12-12.36, p < 0.001) and alleviated gastrointestinal disturbances, such as diarrhea (RR = 0.45, 95% CI: 0.32-0.63, p < 0.001) and constipation (RR = 0.57, 95% CI: 0.42-0.78, p < 0.001). Additionally, inflammatory markers, including IL-6 (SMD = -0.76, 95% CI: -1.05 to -0.47, p < 0.001) and TNF-α (SMD = -0.64, 95% CI: -0.93 to -0.35, p < 0.001), were significantly lowered. Subgroup analyses indicated superior efficacy with multi-strain formulations, higher dosages (≥1010 CFU/day), and extended treatment durations (≥8 weeks).
Conclusion: Current evidence supports the beneficial role of probiotics in restoring gut microbiota balance, enhancing patient well-being, mitigating digestive complications, and reducing systemic inflammation following EC surgery. Further high-quality research is warranted to refine optimal probiotic strains, dosing strategies, and intervention timing.
期刊介绍：
Frontiers in Cellular and Infection Microbiology is a leading specialty journal, publishing rigorously peer-reviewed research across all pathogenic microorganisms and their interaction with their hosts. Chief Editor Yousef Abu Kwaik, University of Louisville is supported by an outstanding Editorial Board of international experts. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
Frontiers in Cellular and Infection Microbiology includes research on bacteria, fungi, parasites, viruses, endosymbionts, prions and all microbial pathogens as well as the microbiota and its effect on health and disease in various hosts. The research approaches include molecular microbiology, cellular microbiology, gene regulation, proteomics, signal transduction, pathogenic evolution, genomics, structural biology, and virulence factors as well as model hosts. Areas of research to counteract infectious agents by the host include the host innate and adaptive immune responses as well as metabolic restrictions to various pathogenic microorganisms, vaccine design and development against various pathogenic microorganisms, and the mechanisms of antibiotic resistance and its countermeasures.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
